Semaglutide for the treatment of overweight and obesity: A review

Keyphrases

• Atherogenic Lipoproteins 14%
• Cardiometabolic Risk 14%
• Caregiver Burden 14%
• Clinical Trials 14%
• Clinically Significant 14%
• Disease-associated 14%
• Gastrointestinal Side Effects 14%
• Glucagon-like 14%
• High Blood Pressure 14%
• Lifestyle Intervention 14%
• Morbidity Mortality 14%
• Multiple Complications 14%
• Obesity 100%
• Obesity-related Diseases 14%
• Once-weekly 14%
• Overweight or Obesity 42%
• People with Obesity 71%
• Pharmacological Treatment 14%
• Physical Function 14%
• Physical Quality 14%
• Placebo 57%
• Quality of Life 14%
• Relapsed Disease 14%
• Safety Profile 14%
• Semaglutide 100%
• Semaglutide 2.4 Mg 100%
• Subcutaneous Semaglutide 14%
• Treatment Effect 71%
• Type 2 Diabetes Mellitus (T2DM) 28%
• Weight Loss 100%

Medicine and Dentistry

• Adverse Event 7%
• Cardiometabolic Risk 7%
• Clinical Trial 7%
• Disease 7%
• Drug Therapy 7%
• Glucagon Like Peptide 1 7%
• Health Care 7%
• Hypertension 7%
• Lifestyle Intervention 7%
• Maturity Onset Diabetes of the Young 15%
• Obesity 100%
• Placebo 30%
• Quality of Life 7%
• Recurrent Disease 7%
• Semaglutide 100%
• Treatment Effect 38%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 7%
• Clinical Trial 7%
• Disease 7%
• Glucagon-Like Peptide-1 7%
• Hypertension 7%
• Non Insulin Dependent Diabetes Mellitus 15%
• Obesity 100%
• Placebo 30%
• Recurrent Disease 7%
• Semaglutide 100%